NCT07093814 A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
| NCT ID | NCT07093814 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Guangzhou Virotech Pharmaceutical Co., Ltd. |
| Condition | Glioblastoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2025-09-02 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 42 participants in total. It began in 2025-09-02 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Eligibility Criteria
Inclusion Criteria: * Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures. * Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female. * Diagnosed with recurrent/progressive glioblastoma. * Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug. * An expected survival time of≥3 months. * Have sufficient organ function. * Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first use of the study drug (if a false-positive pregnancy test result is due to non-pregnancy factors such as illness, further testing via ultrasound or other methods is required, and the investigator must confirm the absence of pregnancy before enrollment). * Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose. Exclusion Criteria: * Patients with extracranial metastases. * Previously received treatment with oncolytic viruses, gene therapy. * Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106. * Subject is known to have an allergic reaction to any of the components of VRT106. * Patients who can't have a cranial MRI scan. * Women who are breastfeeding.
Contact & Investigator
Chengcheng Guo
PRINCIPAL INVESTIGATOR
Sun Yat-Sen University Cancer Center
Frequently Asked Questions
Who can join the NCT07093814 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Glioblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07093814 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07093814 currently recruiting?
Yes, NCT07093814 is actively recruiting participants. Contact the research team at guochch@sysucc.org.cn for enrollment information.
Where is the NCT07093814 trial being conducted?
This trial is being conducted at Hefei, China, Beijing, China, Chongqing, China, Guangzhou, China and 7 additional locations.
Who is sponsoring the NCT07093814 clinical trial?
NCT07093814 is sponsored by Guangzhou Virotech Pharmaceutical Co., Ltd.. The principal investigator is Chengcheng Guo at Sun Yat-Sen University Cancer Center. The trial plans to enroll 42 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.